Benner R, Meima F, Van der Meulen G M, van Ewijk W
Immunology. 1974 Nov;27(5):747-60.
The influence of the route of priming and the dose of sheep red blood cells (SRBC) on the IgM-, IgG- and IgA-plaque-forming cell (PFC) activity in mouse bone marrow during the secondary response to SRBC was studied. After intraperitoneal and subcutaneous priming the number of IgM-, IgG- and IgA-PFC during the secondary response increased with the number of SRBC used for priming. After intravenous (i.v.) priming the priming dose—secondary response relationship was found to be an optimum curve for IgM-PFC as well as for IgG- and IgA-PFC. A peak secondary response in the bone marrow was found after priming with 10 and with 10 SRBC i.v. The appearance of IgG- and IgA-memory cells in the bone marrow after i.v. immunization with SRBC was shown to be dependent on the priming dose: the appearance of IgG-memory cells required a higher dose of SRBC than the appearance of IgM-memory cells, and the appearance of IgA-memory cells required even more antigen. The effect of the booster dose upon the PFC activity was studied in mice primed with 10 SRBC i.v. and boosted with 10, 10, or 10 SRBC i.v. 2 months later. IgM-PFC as well as IgG- and IgA-PFC were present in spleen and bone marrow at each booster dose tested. In each group of mice the PFC activity in the bone marrow rose to a level which surpassed the level in the other lymphoid organs between the 7th and 10th day after the booster injection. Thus, independently of the booster dose, mouse bone marrow is the major source of PFC during the late phase of the secondary response to SRBC. Mice boosted with 10 SRBC i.v. showed a prolonged presence of IgM-, IgG- and IgA-PFC in the thymus. Light and electron microscopic studies revealed the presence of plasma cells and macrophages studded with phagocytosed material in the thymic medulla of these mice, thus providing evidence for a real PFC response within the thymus. A thymic PFC response was absent in mice boosted with either 10 or 10 SRBC i.v. Therefore the thymic PFC activity during the secondary response to SRBC does depend on the booster dose.
研究了致敏途径和绵羊红细胞（SRBC）剂量对小鼠骨髓在再次应答于SRBC期间IgM、IgG和IgA斑块形成细胞（PFC）活性的影响。腹腔内和皮下致敏后，再次应答期间IgM、IgG和IgA - PFC的数量随用于致敏的SRBC数量增加而增加。静脉内（i.v.）致敏后，致敏剂量与再次应答的关系对于IgM - PFC以及IgG和IgA - PFC而言均为一条最佳曲线。静脉注射10个和10个SRBC致敏后，在骨髓中发现了再次应答的峰值。静脉注射SRBC免疫后，骨髓中IgG和IgA记忆细胞的出现显示取决于致敏剂量：IgG记忆细胞的出现需要比IgM记忆细胞更高剂量的SRBC，而IgA记忆细胞的出现则需要更多的抗原。在静脉注射10个SRBC致敏并于2个月后分别静脉注射10个、10个或10个SRBC加强免疫的小鼠中，研究了加强剂量对PFC活性的影响。在所测试的每个加强剂量下，脾脏和骨髓中均存在IgM - PFC以及IgG和IgA - PFC。在每组小鼠中，骨髓中的PFC活性在加强注射后第7天至第10天之间升至超过其他淋巴器官中的水平。因此，与加强剂量无关，小鼠骨髓是再次应答于SRBC后期PFC的主要来源。静脉注射10个SRBC加强免疫的小鼠在胸腺中显示IgM、IgG和IgA - PFC存在时间延长。光镜和电镜研究揭示了这些小鼠胸腺髓质中存在充满吞噬物质的浆细胞和巨噬细胞，从而为胸腺内真正的PFC应答提供了证据。静脉注射10个或10个SRBC加强免疫的小鼠中不存在胸腺PFC应答。因此，再次应答于SRBC期间胸腺的PFC活性确实取决于加强剂量。
Zotero 插件
